Replies to post #100627 on NanoViricides Inc. (NNVC)

[robi-1-kenobi]

Correction - Costs other than FluCide as percentage of R&D got me worked up. Here are the correct figures from the 10K filing for FY 2014.

FluCide $2.0M
DengueCide $0.6M
EKC-Cide $0.1M
HIV-Cide $0.4M
HerpCide $0.6M
Other (Ebola, etc) $0.1M

So all other project costs for R&D add up to $1.8M - almost as much as the labor and spend for FluCide at $2.0M.

With delays and issues on their lead candidate, labor costs and spending for their lead candidate FluCide should have been at least 70-80% of their R&D budget spend.

And now they say there will likely be a capital raise (dilution) before clinical trials? Time for some focus on FluCide.

Ebola is fine as the spend is minimal for a potential to bring in outside revenue if initial (and low cost) testing is successful.

But FluCide needs priority focus, smart project management and execution.

We will see.